TrialScientific reports2022

Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.

Kentaro Ejiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.